Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

An Open Prospective Study for the Use of Rapamycin after High-Risk-Keratoplasty – First Results of a Pilot Study

Birnbaum F.1, Reinhard T.2, Sokolowska J.1, Mayer K.1, Reis A.1, Oellerich M.3, Sundmacher R.1
1Eye-Hospital, Heinrich-Heine University, 2Eye Hospital, Albert-Ludwigs-University, Freiburg; 3Center of Internal Medicine, Department of Clinical Chemistry, Georg-August University, Goettingen

Purpose: Until now CSA and MMF are the only available systemic immunosuppressants for patients undergoing high-risk-keratoplasty. Regarding side-effects and individual intolerances the clinical testing of alternative immunosuppressants is desirable. Rapamycin has shown its immunosuppressive potential in the rat keratoplasty model. After kidney-transplantations Rapamycin is part of several immunosuppressive protocols. Aim of this study was to prove the effectiveness and safety of Rapamycin after penetrating high-risk-keratoplasty.
Method: Ten patients undergoing high-risk-keratoplasty were included in this study. Postoperative medication was Fluocortolon 1 mg/kg/d (tapered off within 3 weeks) and Prednisolonacetate eye-drops 5x/d (tapered off within 5 months). Rapamycin was administered orally once daily (blood-trough-level 4-10 ng/ml) for 6 months. Thereafter, it was tapered off within 2 weeks.
Results: Mean follow-up is 148 days. Until now no immune reactions occurred. 8 patients had partly reversible side-effects as hypercholesteremia, furunculosis,


Zurück | Back